Communiqué de presse – Sunshine Biopharma

Communiqués de presse

DATE

Communiqués de presse

Août 31, 2026

Santé Canada approuve l’aténolol de Sunshine Biopharma pour le traitement et la prise en charge des maladies cardiovasculaires

Août 26, 2026

Sunshine Biopharma fait état d’une suppression tumorale in vivo avec l’ARNm K1.1 et fait progresser une nouvelle stratégie de vaccin anticancéreux à ARNm contre le cancer du poumon

Août 19, 2026

Sunshine Biopharma obtient l’approbation réglementaire canadienne pour l’énalapril, élargissant sa présence sur le marché mondial des antihypertenseurs évalué à 25,94 milliards de dollars

Août 07, 2026

Sunshine Biopharma lance l’amoxicilline au Canada et commence les expéditions aux pharmacies, ciblant un marché mondial estimé à 4,9 milliards de dollars

Août 04, 2026

Sunshine Biopharma fait son entrée sur le marché mondial du diénogest, estimé à 2,8 milliards de dollars, grâce à une approbation réglementaire au Canada

Juil 28, 2026

Santé Canada approuve l’ondansétron de Sunshine Biopharma pour le traitement des nausées et vomissements induits par la chimiothérapie

Juil 20, 2026

Sunshine Biopharma et l’Université de l’Arizona publient d’importants nouveaux résultats de recherche

Juin 25, 2026

Sunshine Biopharma obtient l’approbation réglementaire canadienne pour la version générique d’Arimidex®

Juin 01, 2026

Sunshine Biopharma annonce l’approbation canadienne du rivaroxaban, une version générique de Xarelto®

Mai 29, 2026

Sunshine Biopharma annonce la délivrance du brevet américain 12,624,066 B2 couvrant une nouvelle technologie de traitement du coronavirus

Mai 28, 2026

Sunshine Biopharma annonce un regroupement d’actions afin de maintenir sa cotation au NASDAQ

Mai 21, 2026

Sunshine Biopharma obtient l’approbation réglementaire canadienne pour son amoxicilline générique

Mai 19, 2026

Sunshine Biopharma Inc. annonce la clôture d’une offre publique pouvant atteindre 18,0 millions de dollars

Mai 18, 2026

Sunshine Biopharma Inc. annonce le prix de son offre publique de 6,0 millions de dollars

Avr 06, 2026

Sunshine Biopharma affiche des revenus de 36,3 millions de dollars pour l’exercice 2025, en hausse de 4,1 % par rapport à l’exercice précédent

Oct 28, 2025

Sunshine Biopharma obtient au Canada une autorisation équivalente à celle de la FDA pour la dompéridone afin de traiter les nausées liées au cancer

Oct 20, 2025

SUNSHINE BIOPHARMA LANCE UN TRAITEMENT À LA DOXYCYCLINE POUR LES IST, L’ACNÉ ET LA MALADIE DE LYME

Oct 16, 2025

SUNSHINE BIOPHARMA LANCE LE MÉDICAMENT ANTICHOLESTÉROL PRAVASTATINE

Oct 14, 2025

SUNSHINE BIOPHARMA ALLOUE 5 MILLIONS DE DOLLARS À UN INVESTISSEMENT EN BITCOIN COMME ACTIF DE RÉSERVE STRATÉGIQUE AFIN DE RENFORCER LA RÉSILIENCE DE SA TRÉSORERIE

Oct 09, 2025

SUNSHINE BIOPHARMA ET L’UNIVERSITÉ DE L’ARIZONA DÉVELOPPENT UNE NOUVELLE SÉRIE PUISSANTE D’INHIBITEURS DE PROTÉASE POUR LE TRAITEMENT DES INFECTIONS AU CORONAVIRUS SARS

Juil 02, 2025

SUNSHINE BIOPHARMA LAUNCHES NIOPEG® INTO $10 BILLION BIOLOGICS MARKET

Juin 11, 2025

SUNSHINE BIOPHARMA COMMERCIALISE LE GABAPENTIN GÉNÉRIQUE POUR LA DOULEUR NEUROPATHIQUE AU CANADA, DANS LE SEGMENT CANADIEN D’UN MARCHÉ MONDIAL ÉVALUÉ À 1,92 MILLIARD DE DOLLARS

Mai 15, 2025

SUNSHINE BIOPHARMA PUBLIE SES RÉSULTATS DU PREMIER TRIMESTRE 2025 : REVENUS EN HAUSSE DE 18 % PAR RAPPORT À LA MÊME PÉRIODE L’ANNÉE DERNIÈRE

Mai 06, 2025

SUNSHINE BIOPHARMA COMMERCIALISE LE LURASIDONE GÉNÉRIQUE POUR LE TRAITEMENT DE LA SCHIZOPHRÉNIE AU CANADA, DANS LE CADRE D’UN MARCHÉ MONDIAL ÉVALUÉ À 1,2 MILLIARD DE DOLLARS

Avr 21, 2025

SUNSHINE BIOPHARMA COMMERCIALISE L’EVEROLIMUS AU CANADA, UN MÉDICAMENT ONCOLOGIQUE DONT LE MARCHÉ MONDIAL ESTIMÉ S’ÉLÈVE À 2,5 MILLIARDS DE DOLLARS

Avr 03, 2025

SUNSHINE BIOPHARMA INC. ANNONCE LA CLÔTURE D’UN FINANCEMENT EN PLACEMENT DIRECT ENREGISTRÉ DE 2,46 MILLIONS DE DOLLARS

Avr 02, 2025

SUNSHINE BIOPHARMA INC. ANNONCE UN FINANCEMENT EN PLACEMENT DIRECT ENREGISTRÉ DE 2,46 MILLIONS DE DOLLARS, AU PRIX DU MARCHÉ CONFORMÉMENT AUX RÈGLES DU NASDAQ

Avr 02, 2025

SUNSHINE BIOPHARMA ANNONCE DES RÉSULTATS POSITIFS DE SA THÉRAPIE À ARN MESSAGER CONTRE LE CANCER

Avr 01, 2025

SUNSHINE BIOPHARMA RAPPORTE DES REVENUS DE 34,9 M$ POUR L’EXERCICE 2024, EN HAUSSE DE 45 % PAR RAPPORT À L’AN DERNIER

Mar 24, 2025

SUNSHINE BIOPHARMA ACCROÎT SA PRÉSENCE SUR LE MARCHÉ MONDIAL DES ANTIBIOTIQUES ÉVALUÉ À 53,9 MILLIARDS DE DOLLARS GRÂCE À L’ACQUISITION DES DROITS DE COMMERCIALISATION DE DEUX NOUVEAUX ANTIBIOTIQUES AU CANADA

Mar 10, 2025

SUNSHINE BIOPHARMA ACQUIERT LES DROITS DE COMMERCIALISATION DEUX MÉDICAMENTS GASTRO-INTESTINAUX SUR LE MARCHÉ CANADIEN DE 200 MILLIONS DE DOLLARS

Jan 21, 2025

SUNSHINE BIOPHARMA ÉLARGIT SA GAMME DE PRODUITS À 69 MÉDICAMENTS GÉNÉRIQUES SUR ORDONNANCE EN LANCANT L’OLANZAPINE ET L’OLANZAPINE ODT

Jan 15, 2025

SUNSHINE BIOPHARMA ANNONCE LA NOMINATION D’UN NOUVEAU CHEF DES AFFAIRES COMMERCIALES

Déc 09, 2024

SUNSHINE BIOPHARMA ANNONCE UN NOUVEL INHIBITEUR CONTRE LE CORONAVIRUS SARS

Déc 04, 2024

SUNSHINE BIOPHARMA LANCE UN NOUVEAU MÉDICAMENT GÉNÉRIQUE SUR ORDONNANCE

Déc 02, 2024

SUNSHINE BIOPHARMA ANNONCE DES RÉSULTATS DE RECHERCHE RÉVOLUTIONNAIRES SUR SON PRODUIT À BASE D’ARNm K1.1 COMME NOUVEL AGENT THÉRAPEUTIQUE CONTRE LE CARCINOME HÉPATOCELLULAIRE CHEZ L’HUMAIN

Nov 22, 2024

SUNSHINE BIOPHARMA LANCE UN NOUVEAU MÉDICAMENT GÉNÉRIQUE SUR ORDONNANCE

Nov 06, 2024

SUNSHINE BIOPHARMA PUBLIE LES RÉSULTATS DU TROISIÈME TRIMESTRE 2024 : REVENUS CUMULÉS EN HAUSSE DE 54 %

Sep 26, 2024

SUNSHINE BIOPHARMA LANCE DEUX NOUVEAUX MÉDICAMENTS GÉNÉRIQUES SUR ORDONNANCE

Sep 04, 2024

SUNSHINE BIOPHARMA ANNONCE LA PUBLICATION DE RÉSULTATS DE RECHERCHE IMPORTANTS SUR LE CORONAVIRUS DANS LE JOURNAL OF MEDICINAL CHEMISTRY

Août 26, 2024

SUNSHINE BIOPHARMA A LANCÉ NEUF NOUVEAUX MÉDICAMENTS GÉNÉRIQUES SUR ORDONNANCE EN 2024 : COMMERCIALISE DÉSORMAIS SOIXANTE ET UN MÉDICAMENTS GÉNÉRIQUES AU CANADA

Août 19, 2024

SUNSHINE BIOPHARMA PUBLIE LES RÉSULTATS DU DEUXIÈME TRIMESTRE 2024 : REVENUS DU T2 EN HAUSSE DE 67 %, REVENUS CUMULÉS EN HAUSSE DE 61 %

Août 06, 2024

SUNSHINE BIOPHARMA ANNONCE UN REGROUPEMENT D’ACTIONS (REVERSE STOCK SPLIT)

Mai 21, 2024

SUNSHINE BIOPHARMA PUBLIE LES RÉSULTATS DU PREMIER TRIMESTRE 2024 : REVENUS EN HAUSSE DE 54 %

Avr 19, 2024

SUNSHINE BIOPHARMA ANNONCE QUE SA FILIALE NORA PHARMA A REÇU L’APPROBATION DE SANTÉ CANADA POUR NIOPEG®, UN BIOSIMILAIRE DE NEULASTA®

Avr 12, 2024

SUNSHINE BIOPHARMA ANNONCE UN REGROUPEMENT D’ACTIONS INVERSÉ (REVERSE STOCK SPLIT)

Avr 01, 2024

SUNSHINE BIOPHARMA PUBLIE LES RÉSULTATS DE L’EXERCICE CLOS LE 31 DÉCEMBRE 2023

Fév 15, 2024

SUNSHINE BIOPHARMA, INC. ANNONCE LA CLÔTURE DE SON OFFRE PUBLIQUE GARANTIE DE 10,0 MILLIONS DE DOLLARS

Fév 13, 2024

SUNSHINE BIOPHARMA, INC. ANNONCE LE PRIX DE SON OFFRE PUBLIQUE GARANTIE DE 10,0 MILLIONS DE DOLLARS

Déc 04, 2023

SUNSHINE BIOPHARMA DÉMÉNAGE SON SIÈGE SOCIAL À NEW YORK

Nov 13, 2023

SUNSHINE BIOPHARMA REPORTS 2023 THIRD QUARTER RESULTS: REVENUES UP SIGNIFICANTLY OVER LAST YEAR DUE TO A KEY ACQUISITION

Sep 21, 2023

SUNSHINE BIOPHARMA RECEIVES 180-DAY EXTENSION TO ACHIEVE NASDAQ MINIMUM BID COMPLIANCE

Sep 19, 2023

SUNSHINE BIOPHARMA ANNOUNCES SHARE REPURCHASE PROGRAM

Août 11, 2023

SUNSHINE BIOPHARMA REPORTS 2023 SECOND QUARTER RESULTS: REVENUES UP 3,600%

Mai 16, 2023

SUNSHINE BIOPHARMA ANNOUNCES of $5.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

Mai 12, 2023

SUNSHINE BIOPHARMA ANNOUNCES PRICING OF $5.0 MILLION PRIVATE PLACEMENT PRICED AT THE MARKET

Mai 11, 2023

SUNSHINE BIOPHARMA REPORTS 2023 FIRST QUARTER RESULTS: REVENUES UP 2,100%

Mai 05, 2023

SUNSHINE BIOPHARMA REPORTS FULL YEAR ENDED DECEMBER 31, 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fév 28, 2023

SUNSHINE BIOPHARMA SIGNS EXCLUSIVE WORLDWIDE LICENSE WITH UNIVERSITY OF ARIZONA FOR PLPRO-BASED COVID-19 TREATMENT

Fév 10, 2023

SUNSHINE BIOPHARMA SIGNS RESEARCH AGREEMENT WITH THE JEWISH GENERAL HOSPITAL TO ADVANCE THE DEVELOPMENT OF ADVA-27A ANTICANCER COMPOUND

Déc 20, 2022

SUNSHINE BIOPHARMA’S ANNUAL LETTER TO SHAREHOLDERS

Nov 16, 2022

SUNSHINE BIOPHARMA ENTERS INTO COLLABORATION WITH A LEADING LIPID NANOPARTICLE FORMULATION COMPANY FOR ITS K1.1 ANTICANCER MRNA PROJECT

Oct 20, 2022

SUNSHINE BIOPHARMA ANNOUNCES THE ACQUISITION OF NORA PHARMA, ADDING $10.7 MILLION IN REVENUE

Juil 28, 2022

SUNSHINE BIOPHARMA INCREASES SUPPORT FOR ANTI-CORONAVIRUS COLLABORATIVE RESEARCH WITH THE UNIVERSITY OF ARIZONA

Avr 28, 2022

SUNSHINE BIOPHARMA, INC. ANNOUNCES CLOSING OF $19.5 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

Avr 26, 2022

SUNSHINE BIOPHARMA, INC. ANNOUNCES PRICING OF $19.5 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

Avr 25, 2022

SUNSHINE BIOPHARMA FILES PATENT APPLICATION COVERING RECENTLY ANNOUNCED MRNA MOLECULES…

Avr 05, 2022

SUNSHINE BIOPHARMA’S NEWLY DESIGNED MRNA MOLECULES PROVE EFFECTIVE AGAINST MULTIDRUG RESISTANT CANCER CELLS

Mar 14, 2022

SUNSHINE BIOPHARMA, INC. ANNOUNCES CLOSING OF $8.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

Mar 10, 2022

SUNSHINE BIOPHARMA, INC. ANNOUNCES PRICING OF $8.0 MILLION PRIVATE PLACEMENT PRICED AT-THE-MARKET

Fév 25, 2022

SUNSHINE BIOPHARMA EXPANDS ANTI-CORONAVIRUS DRUG DEVELOPMENT PROGRAM BY SIGNING A COLLABORATION AGREEMENT WITH THE UNIVERSITY OF ARIZONA

Fév 15, 2022

SUNSHINE BIOPHARMA INC. ANNOUNCES PRICING OF $8 MILLION PUBLIC OFFERING AND UPLISTING TO THE NASDAQ CAPITAL MARKET

Déc 22, 2021

SUNSHINE BIOPHARMA ANNOUNCES $1,361,000 IN DEBT REDUCTION

Nov 03, 2021

SUNSHINE BIOPHARMA EXPANDS BOARD OF DIRECTORS

Oct 06, 2021

SUNSHINE BIOPHARMA FILES A PATENT APPLICATION COVERING MRNA MOLECULES…

Août 12, 2021

SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST DELTA AND THE OTHER VARIANTS OF CONCERN

Juil 27, 2021

SUNSHINE BIOPHARMA OPENS TWITTER ACCOUNT FOR INCREASED SHAREHOLDER ENGAGEMENT

Juil 20, 2021

SUNSHINE BIOPHARMA RECEIVES $0.9 MILLION IN ADDITIONAL FUNDING FROM RB CAPITAL

Juil 08, 2021

SUNSHINE BIOPHARMA EMPLOYS MRNA VACCINE TECHNOLOGY TO EXPAND ITS FIGHT AGAINST MULTIDRUG RESISTANT CANCER

Juin 09, 2021

SUNSHINE BIOPHARMA MICE STUDY FOR COVID-19 TREATMENT PROGRESSING AS PLANNED

Mai 23, 2021

SUNSHINE BIOPHARMA UPGRADES COVID-19 PROVISIONAL PATENT APPLICATION TO FULL PCT APPLICATION

Mai 20, 2021

SUNSHINE BIOPHARMA ELIMINATES $250,000 IN VARIABLE RATE CONVERTIBLE DEBT AND PROVIDES AN UPDATE ON STATUS OF OTCQB UPLISTING

Mai 13, 2021

SUNSHINE BIOPHARMA REPORTS IMPROVED CASH POSITION IN 2021Q1 FILING

Avr 23, 2021

SUNSHINE BIOPHARMA REPORTS FAVORABLE MTD RESULTS FOR COVID-19 TREATMENT

Avr 22, 2021

RB CAPITAL INCREASES INVESTMENT IN SUNSHINE BIOPHARMA

Mar 23, 2021

SUNSHINE BIOPHARMA REACHES $2,000,000+ FINANCING FOR CORONAVIRUS TREATMENT

Mar 11, 2021

SUNSHINE BIOPHARMA RECEIVES RECENTLY ORDERED NEW BATCH OF ADVA-27A AND INITIATES QA/QC TESTING

Mar 11, 2021

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF ADVA-27A IN EUROPE UNTIL 2033

Mar 01, 2021

SUNSHINE BIOPHARMA LAUNCHES ONLINE STORE FOR ITS SCIENCE-BASED NUTRITIONAL SUPPLEMENTS

Fév 18, 2021

SUNSHINE BIOPHARMA DISCUSSES THE PROGRESS OF ITS COVID-19 AND ANTICANCER COMPOUNDS WITH THE STOCK DAY PODCAST

Fév 10, 2021

SUNSHINE BIOPHARMA INITIATES COVID-19 TREATMENT MICE STUDY

Fév 04, 2021

SUNSHINE BIOPHARMA SIGNS EXCLUSIVE LICENSE AGREEMENT WITH UNIVERSITY OF GEORGIA FOR COVID-19 COMPOUNDS

Fév 02, 2021

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF ADVA-27A IN CANADA UNTIL 2033

Jan 27, 2021

SUNSHINE BIOPHARMA COMPLETES APPLICATION TO UPLIST TO OTCQB

Jan 14, 2021

SUNSHINE BIOPHARMA RECEIVES FOURTH TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Déc 03, 2020

SUNSHINE BIOPHARMA PAYS OFF CONVERTIBLE NOTES IN CASH PREVENTING NEW SHARES FROM HITTING THE MARKET

Déc 02, 2020

SUNSHINE BIOPHARMA’S CORONAVIRUS TREATMENT ANTICIPATED TO BE EFFECTIVE AGAINST THE NEW VARIANT IDENTIFIED IN THE UK

Déc 01, 2020

SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 PLUS FINANCING FOR CORONAVIRUS TREATMENT

Nov 24, 2020

SUNSHINE BIOPHARMA BELIEVES THAT AN EFFECTIVE CORONAVIRUS TREATMENT CONTINUES TO BE NECESSARY

Nov 18, 2020

SUNSHINE BIOPHARMA RECEIVES THIRD TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 PLUS FINANCING FOR CORONAVIRUS TREATMENT

Nov 10, 2020

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT FOR DISTRIBUTION OF ESSENTIAL-9TM IN ASIA AND THE FAR EAST

Oct 26, 2020

SUNSHINE BIOPHARMA RECEIVES SECOND TRANCHE FROM PREVIOUSLY ANNOUNCED $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Oct 19, 2020

SUNSHINE BIOPHARMA AND UNIVERSITY OF GEORGIA TEAM UP TO DEVELOP A NEW ANTI-CORONAVIRUS DRUG

Oct 07, 2020

SUNSHINE BIOPHARMA IDENTIFIES A LEAD ANTI-CORONAVIRUS COMPOUND

Sep 15, 2020

SUNSHINE BIOPHARMA SECURES $2,000,000 + FINANCING FOR CORONAVIRUS TREATMENT

Août 25, 2020

SUNSHINE BIOPHARMA COMPLETES THE SYNTHESIS OF FOUR POTENTIAL INHIBITORS OF CORONAVIRUS PROTEASE

Août 08, 2020

SUNSHINE BIOPHARMA ORDERS A NEW BATCH OF ADVA-27A FOR TESTING ON TOPII AMPLIFIED CANCERS

Jan 03, 2020

SUNSHINE BIOPHARMA FILES A PATENT APPLICATION FOR A NEW CORONAVIRUS COVID-19 TREATMENT

Nov 06, 2019

SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL CALCIUM-VITAMIN DTM SUPPLEMENT

Oct 17, 2019

SUNSHINE BIOPHARMA INITIATES ADVA-27A XENOGRAFT STUDIES IN MICE CARRYING DIFFERENT TYPES OF HUMAN CANCER<

Sep 03, 2019

SUNSHINE BIOPHARMA RECEIVES VEGAN CERTIFICATION FOR ESSENTIAL 9™ AMINO ACIDS SUPPLEMENT

Mai 28, 2019

IN ADDITION TO ESSENTIAL 9™, SUNSHINE BIOPHARMA LAUNCHES 7 NEW DIETARY SUPPLEMENTS NOW AVAILABLE ON AMAZON.CA

Mai 16, 2019

SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE IN THE UNITED STATES ON AMAZON.COM

Mar 12, 2019

SUNSHINE BIOPHARMA ANNOUNCES THAT ESSENTIAL 9™ IS NOW AVAILABLE ON AMAZON.CA

Fév 04, 2019

SUNSHINE BIOPHARMA RECEIVES NOTICE OF ALLOWANCE FOR A NEW PATENT APPLICATION EXTENDING PROTECTION OF ADVA-27A ANTICANCER DRUG UNTIL 2033

Déc 17, 2018

SUNSHINE BIOPHARMA RECEIVES HEALTH CANADA APPROVAL FOR ESSENTIAL 9™, THE COMPANY’S FIRST OVER THE COUNTER ESSENTIAL MICRONUTRIENT

Déc 12, 2018

SUNSHINE BIOPHARMA SIGNS AN AGREEMENT WITH CROCUS LABORATORIES FOR MANUFACTURING OF ADVA-27A ANTICANCER DRUG

Sep 14, 2018

SUNSHINE BIOPHARMA ANNOUNCES $10 MILLION EQUITY FINANCING

Août 16, 2018

SUNSHINE BIOPHARMA SIGNS A SERVICE AGREEMENT WITH UTAH BASED QUINTESSENTIAL BIOSCIENCES INC.

Juin 18, 2018

SUNSHINE BIOPHARMA LAUNCHES MICROBIOLOGY TESTING SERVICE

Mai 10, 2018

SUNSHINE BIOPHARMA ANNOUCES EXTENSION OF THE TERM OF ITS BROKERED UP TO $10 MILLION PRIVATE PLACEMENT FINANCING

Jan 04, 2018

SUNSHINE BIOPHARMA COMPLETES THE ACQUISITION OF ATLAS PHARMA

Sep 05, 2017

SUNSHINE BIOPHARMA ENTERS INTO AN INVESTMENT BANKING AGREEMENT WITH JITNEY TRADE TO RAISE UP TO $10 MILLION…

Juin 26, 2017

SUNSHINE BIOPHARMA RELEASES RESULTS OF INDEPENDENT VALUATION

Juin 19, 2017

SUNSHINE BIOPHARMA FILES AN APPLICATION WITH HEALTH CANADA FOR A DRUG ESTABLISHMENT LICENSE

Jan 11, 2017

SUNSHINE BIOPHARMA CURRENTLY REVIEWING TWENTY THREE ADDITIONAL GENERIC PRODUCTS FOR IN-LICENSING

Déc 09, 2016

SUNSHINE BIOPHARMA SIGNS STRATEGIC ALLIANCE AGREEMENT WITH ATLAS PHARMA

Juin 30, 2016

SUNSHINE BIOPHARMA SIGNS LICENSING AGREEMENT FOR THREE ADDITIONAL GENERIC PRODUCTS FOR TREATMENT OF CANCER AND BPH

Mai 11, 2016

SUNSHINE BIOPHARMA SIGNS LICENSING AGREEMENT FOR ANASTROZOLE, THE COMPANY’S FIRST GENERIC DRUG FOR TREATMENT OF BREAST CANCER

Mar 15, 2016

SUNSHINE BIOPHARMA ELIMINATES THE DEBT OBLIGATIONS ASSOCIATED WITH THE RECENTLY ACQUIRED PATENTS FOR IT’S ADVA-27A ANTICANCER COMPOUND

Déc 08, 2015

SUNSHINE BIOPHARMA ACQUIRES ALL REMAINING WORLDWIDE PATENTS FOR ITS ADVA-27A ANTICANCER COMPOUND

Oct 09, 2015

SUNSHINE BIOPHARMA ACQUIRES THE US PATENT FOR ITS ANTICANCER COMPOUND, ADVA-27A

Août 04, 2015

SUNSHINE BIOPHARMA ANNOUNCES THAT THE INITIAL MANUFACTURING SAMPLE OF ITS ANTICANCER COMPOUND ADVA-27A…

Mai 26, 2015

SUNSHINE BIOPHARMA TO RECEIVE THIS WEEK A SAMPLE FROM THE ADVA-27A MANUFACTURING CURRENTLY UNDERWAY AT LONZA IN SWITZERLAND

Mar 24, 2015

SUNSHINE BIOPHARMA ANNOUNCES ISSUANCE OF NOTICE OF ALLOWANCE FOR THE PATENT APPLICATION COVERING ADVA-27A ANTICANCER COMPOUND IN INDIA

Fév 25, 2015

SUNSHINE BIOPHARMA ANNOUNCES CHANGE TO ITS BOARD OF DIRECTORS AND OFFICERS

Jan 20, 2015

SUNSHINE BIOPHARMA IS MOVING FORWARD WITH ITS DEVELOPMENT PLANS FOR ADVA-27A ANTICANCER COMPOUND

Nov 19, 2014

SUNSHINE BIOPHARMA SIGNS AGREEMENT WITH LONZA TO MANUFACTURE ITS LEAD ANTICANCER COMPOUND, ADVA-27A

Nov 03, 2014

EBOLA VIRUS INFECTIONS COULD POTENTIALLY BE TREATED WITH SUNSHINE BIOPHARMA’S LEAD ANTICANCER COMPOUND, ADVA-27A

Oct 14, 2014

SUNSHINE BIOPHARMA RETAINS RENMARK FINANCIAL COMMUNICATIONS TO PROVIDE INVESTOR RELATIONS

Oct 01, 2014

SUNSHINE BIOPHARMA’S WHOLLY OWNED CANADIAN SUBSIDIARY COMPLETES THE SOP’S REQUIRED BY HEALTH CANADA TO SECURE DRUG ESTABLISHMENT LICENSE

Sep 03, 2014

SUNSHINE BIOPHARMA NEGOTIATING WITH CRO’S TO INITIATE MASTER DRUG FILE FOR ADVA-27A ANTICANCER COMPOUND

Août 21, 2014

SUNSHINE BIOPHARMA’S WHOLLY OWNED CANADIAN SUBSIDIARY ENGAGES HEALTH CANADA SPECIALIZED CONSULTANTS TO SECURES PHARMACEUTICAL…

Août 11, 2014

SUNSHINE BIOPHARMA’S WHOLLY OWNED CANADIAN SUBSIDIARY SECURES DEDICATED SPACE TO COMMENCE GLOBAL GENERIC PHARMACEUTICAL OPERATIONS

Juin 09, 2014

SUNSHINE BIOPHARMA’S ADVA-27A FEATURED IN 2014 WORLDWIDE UTERINE CANCER REPORT FOR ITS EFFECTIVENESS AGAINST MULTIDRUG RESISTANT UTERINE CANCER CELLS

Mai 12, 2014

SUNSHINE BIOPHARMA ANNOUNCES ISSUANCE OF NOTICE OF ALLOWANCE FOR THE PATENT APPLICATION COVERING ADVA-27A ANTICANCER COMPOUND IN CANADA

Avr 29, 2014

SUNSHINE BIOPHARMA SECURES FUNDING FOR ITS ADVA-27A ANTICANCER COMPOUND FROM DUTCHESS OPPORTUNITY FUND II

Avr 07, 2014

SUNSHINE BIOPHARMA INCREASES THE EFFECTIVENESS OF ADVA-27A LEAD COMPOUND 9.5-FOLD AGAINST BREAST AND PANCREATIC CANCER IN VITRO

Mar 31, 2014

SUNSHINE BIOPHARMA’S ANTICANCER DRUG CANDIDATE, ADVA-27A, IS UNAFFECTED BY THE RECENT SUPREME COURT RULING

Mar 31, 2014

SUNSHINE BIOPHARMA BEGINS CONSTRUCTION OF MOUSE XENOGRAFT MODELS FOR PANCREATIC CANCER TO ADVANCE ADVA-27A….

Mar 31, 2014

MANAGEMENT OF SUNSHINE BIOPHARMA ALARMED BY THE RECENT WORLD HEALTH ORGANIZATION REPORT THAT CANCER IS ON THE RISE

Juin 04, 2013

SUNSHINE BIOPHARMA ANNOUNCES THAT ITS BREAST CANCER DRUG CANDIDATE, ADVA-27A, ALSO DESTROYS PANCREATIC CANCER CELLS

Mai 01, 2013

SUNSHINE BIOPHARMA NARROWS KILOGRAM MANUFACTURING OPTIONS FOR ADVA-27A BREAST CANCER DRUG CANDIDATE TO THREE SUPPLIERS

Avr 10, 2013

SUNSHINE BIOPHARMA HMEC STUDY INDICATES NOVEL ANTICANCER COMPOUND ADVA-27A NON-TOXIC AT HIGH CONCENTRATIONS

Mar 14, 2013

SUNSHINE BIOPHARMA COMMENCES NEGOTIATIONS WITH CONTRACT MANUFACTURING ORGANIZATIONS FOR PRODUCTION OF ITS MULTIDRUG-RESISTANT…

Fév 26, 2013

SUNSHINE BIOPHARMA REPORTS ON IND RESEARCH FOR ITS NOVEL BREAST CANCER DRUG CANDIDATE, ADVA-27A

Jan 15, 2013

ADVANOMICS CORPORATION, THE PARENT COMPANY OF SUNSHINE BIOPHARMA, FILES A NEW PATENT APPLICATION FOR ITS MULTIDRUG RESISTANCE ADVA-27A…

Déc 10, 2012

SUNSHINE BIOPHARMA COMPLETES ANOTHER IND-ENABLING STUDY: ADVA-27A IS FOUND TO BE EFFECTIVE AGAINST MULTIDRUG RESISTANT UTERINE CANCER CELLS

Déc 04, 2012

ADVANOMICS CORPORATION, THE PARENT COMPANY OF SUNSHINE BIOPHARMA, COMPLETES ACQUISITION OF ADVA-27A PATENTS

Déc 04, 2012

SUNSHINE BIOPHARMA COMPLETES SIX IND-ENABLING STUDIES FOR ITS ANTICANCER COMPOUND, ADVA-27A

Nov 13, 2012

SUNSHINE BIOPHARMA RECEIVES SCALE-UP MANUFACTURING PROTOCOL FOR ITS LEAD ANTI-CANCER COMPOUND, ADVA-27A

Nov 13, 2012

SUNSHINE BIOPHARMA INITIATES IND-ENABLING STUDIES FOR ITS ANTICANCER COMPOUND, ADVA-27A

Sep 25, 2012

SUNSHINE BIOPHARMA’S ADVA-27A PRECLINICAL RESEARCH RESULTS TO BE PUBLISHED IN OCT. ISSUE OF ANTICANCER RESEARCH

Sep 20, 2012

BREAST CANCER NEWS: GERON DRUG FAILS, HERCEPTIN® MAY INCREASE HEART PROBLEMS, SUNSHINE BIOPHARMA HEADING FOR CLINICAL TRIALS

Sep 13, 2012

SUNSHINE BIOPHARMA ADVANCES TO NEXT PHASE OF DRUG DEVELOPMENT WITH LEAD ANTI-CANCER COMPOUND, ADVA-27A

Sep 04, 2012

SUNSHINE BIOPHARMA TAKES DELIVERY OF NEWLY MANUFACTURED BATCH OF ADVA-27A AND PROCEEDS TO CONDUCTING BIOLOGICAL VERIFICATION OF…

Août 15, 2012

SUNSHINE BIOPHARAMA ANNOUNCES SUBMISSION OF AN ADVA-27A MANUSCRIPT FOR PUBLICATION IN A PEER-REVIEWED SCIENTIFIC JOURNAL

Août 03, 2012

BUYINS.NET ISSUES SUNSHINE BIOPHARMA SQUEEZE TRIGGER REPORT

Juil 30, 2012

SUNSHINE BIOPHARMA, INC. (OTCBB: SBFM) – TARGETING THE CHALLENGE OF MULTIDRUG RESISTANCE IN BREAST AND LUNG CANCER BY DEVELOPING ADVA-27A

Juil 26, 2012

SUNSHINE BIOPHARMA ENGAGES BETA PHARMA CANADA FOR MANUFACTURING OF AN INITIAL BATCH OF ADVA-27A

Juil 24, 2012

BIOTECH INVESTOR ALERT: CFO OF SUNSHINE BIOPHARMA EXPANDS ON SIGNIFICANCE OF RECENT MANUFACTURING NEWS OF LEAD ANTI-CANCER COMPOUND ADVA-27A

Juil 19, 2012

TARGETING AGGRESSIVE FORMS OF CANCER: SUNSHINE BIOPHARMA (OTCBB:SBFM) AND ROCHE (SIX: RO, ROG; OTCQX: RHHBY)

Juil 11, 2012

SUNSHINE BIOPHARMA ENGAGES BETA PHARMA CANADA FOR MANUFACTURING OF AN INITIAL BATCH OF ADVA-27A

Juil 02, 2012

BIOTECH INVESTOR Q&A WITH CFO OF SUNSHINE BIOPHARMA (OTCBB:SBFM) DISCUSSING ITS LEAD COMPOUND – ADVA-27A FOR AGGRESSIVE FORMS OF CANCER

Mai 22, 2012

PHARMACOKINETICS PARAMETERS OF SUNSHINE BIOPHARMA’S LEAD ANTI-CANCER COMPOUND EXCEED EXPECTATIONS

Avr 09, 2012

SUNSHINE BIOPHARMA ANNOUNCES ISSUANCE OF NOTICE OF ALLOWANCE FOR THE PATENT APPLICATION COVERING ITS ADVA-27A ANTI-CANCER COMPOUND

Mar 26, 2012

SUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY TO PRESENT NEW DATA AT THE UPCOMING AMERICAN ASSOCIATION FOR CANCER RESEARCH MEETING IN CHICAGO

Nov 28, 2011

AVASTIN OUSTED BY FDA FOR BREAST CANCER, SUNSHINE BIOPHARMA GEARS-UP FOR CLINICALS

Oct 15, 2011

SUNSHINE BIOPHARMA’S ANNOUNCES SUCCESSFUL COMPLETION OF PRECLINICAL STUDIES FOR ADVA-27A, THE COMPANY’S LEAD ANTI-CANCER COMPOUND

Oct 05, 2011

SUNSHINE BIOPHARMA’S ANTI-CANCER COMPOUND, ADVA-27A, FOUND TO BE A TOPOISOMERASE II INHIBITOR

Août 30, 2011

CLEARANCE OF SUNSHINE BIOPHARMA’S ANTI-CANCER COMPOUND, ADVA-27A, DOES NOT INVOLVE A TOXIC INTERMEDIATE

Juil 27, 2011

SUNSHINE BIOPHARMA LOOKING TO MIMIC ROCHE’S BILLION DOLLAR CANCER DRUG SUCCESS

Juil 25, 2011

SUNSHINE BIOPHARMA’S LEAD ANTI-TUMOR COMPOUND, ADVA-27A, IS CLEARED VIA A CYTOCHROME P450-INDEPENDENT MECHANISM

Juil 11, 2011

SUNSHINE BIOPHARMA’S ADVA-27A IS 16-TIMES MORE EFFECTIVE AT KILLING MULTIDRUG RESISTANT BREAST CANCER CELLS

Juin 17, 2011

SUNSHINE BIOPHARMA ENTERS INTO CLINICAL TRIALS AGREEMENT WITH THE JEWISH GENERAL HOSPITAL IN MONTREAL, CANADA

Avr 01, 2011

SUNSHINE BIOPHARMA’S CEO DOES LIVE INTERVIEW ON CHARTPOPPERS.COM

Mar 27, 2011

SUNSHINE BIOPHARMA’S LEAD ANTI-CANCER COMPOUND, ADVA-27A, PERFORMS EXCEPTIONALLY WELL IN HUMAN MICROSOME STABILITY ASSAYS

Mar 04, 2011

CEO CFO INTERVIEWS DR. STEVE N. SLILATY

Jan 26, 2011

FOX 40 WICZ.COM INTERVIEW OF BINGHAMTON UNIVERSITY ON SUNSHINE BIOPHARMA PART 1

Jan 21, 2011

SUNSHINE BIOPHARMA AND BINGHAMTON UNIVERSITY (STATE UNIVERSITY OF NEW YORK) ENTER INTO RESEARCH AGREEMENT

Oct 13, 2010

SUNSHINE BIOPHARMA, INC. BEGINS DRUG DEVELOPMENT ACTIVITIES

Oct 13, 2010

CEOCAST INTERVIEW WITH DR. STEVE SLILATY OF SUNSHINE BIOPHARMA INC.

Oct 20, 2009

MOUNTAIN WEST BUSINESS SOLUTIONS ACQUIRES SUNSHINE BIOPHARMA